CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 3556550
• 负责人: DAVID B DUGGAN
• 金额: $ 16.95万
• 依托单位: UPSTATE MEDICAL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-04-01 至 1998-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556550
• 关键词: Hodgkin's disease; acute lymphocytic leukemia; acute myelogenous leukemia; bleomycin; breast neoplasms; cis platinum compound; clinical trials; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; dacarbazine; doxorubicin; etoposide; fluorouracil; gastrointestinal neoplasms; hairy cell leukemia; human subject; human therapy evaluation; ifosfamide; interferons; interleukin 2; library; lung neoplasms; lymphoma; mechlorethamine; methotrexate; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; pharmacokinetics; prednisone; procarbazine; tumor antigens; vinblastine; vincristine

The proposal requests continuation funding for institutional participation of the SUNY Health Science Center at Syracuse, New York, in the research activities of Cancer and Leukemia Group B (CALGB). CALGB is a multi-institutional cooperative research group dedicated to the systematic planning, conduct, analysis, and reporting of research as applied to therapy of patients with malignant disease. The scope of interest of CALGB and our institutional participation focuses on therapy of leukemias, lymphomas, and cancers of the lung, breast, and GI tract, as well as laboratory based evaluations. CALGB participation at SUNY-HSC is interdisciplinary, involving the active participation of General and Thoracic Surgery, Radiotherapy, Pathology, Psychiatry, Cytogenetics and Internal Medicine (Hematology and Medical Oncology). The SUNY-HSC actively participates in all phases of the CALGB program. Our personnel contribute heavily to, and are prominent in, group scientific and administrative leadership, new study design and chairmanship, development and execution of pilot studies and the testing of new chemotherapeutic agents in phase I and phase II trials in addition to the accrual of greater the 220 patient entries/year to group protocols. The Leukemia Reference Laboratory for the group is located at our institution. As a result of the funding provided by this proposal and our institutional commitment, the accrual rate for patients entered into controlled, evaluable, experimental cancer therapy will be maintained at the current high level. The broadening and deepening of the clinical research program at our institution will similarly be reflected in the depth and breadth of our scientific and administrative involvement in CALGB activities. Since our institutional participation with CALGB is the core of the interdisciplinary cancer program at our institution, additional salutary effects will continue to be evident in the education of medical students, house officers, nursing staff as well as in the continuing education of physicians in Upstate New York. In addition, the collaboration with CALGB will help translate the most recent advances in medical care and expertise to a large and diversified patient population. Through our established outreach efforts, new advances in cancer therapy will be rapidly disseminated to large groups of patients in Central New York.

该提案要求继续提供资金， 纽约州立大学健康科学中心在锡拉丘兹，纽约的参与， 癌症和白血病组B（CALGB）的研究活动。 CALGB是 一个多机构合作研究小组，致力于 系统地规划、开展、分析和报告研究， 用于恶性疾病患者的治疗。 的范围 CALGB的兴趣和我们的机构参与侧重于治疗 白血病、淋巴瘤、肺癌、乳腺癌和胃肠道癌， 以及基于实验室的评估。 CALGB参加SUNY-HSC 是跨学科的，涉及一般和 胸外科、放射治疗、病理学、精神病学、细胞遗传学和 内科学（血液学和内科肿瘤学）。 SUNY-HSC 积极参与CALGB计划的各个阶段。 我们的人员 在科学和技术领域做出了重大贡献，并在其中表现突出， 行政领导，新的研究设计和主席，发展 进行试点研究和测试新的化疗药物， I期和II期试验中的药物， 大于220例患者条目/年的分组方案。 白血病 该小组的参考实验室位于我们的机构。 作为 这一建议和我们的机构提供的资金的结果 承诺，进入受控的患者的增加率， 可评估的实验性癌症治疗将维持在目前的水平。 高水平 临床研究的拓宽与深化 在我们的机构计划将同样反映在深度和 我们在CALGB的科学和行政参与的广度 活动 由于我们与CALGB的机构参与是核心 在我们机构的跨学科癌症项目中， 有益的影响将继续在医学教育中显现出来。 学生，内务人员，护理人员以及在继续 纽约北部的医生教育。 此外该 与CALGB的合作将有助于将最新的进展转化为 医疗护理和专业知识，以大量和多样化的患者群体。 通过我们建立的外展工作，癌症治疗的新进展 将迅速传播到大量的病人在中央新 约克。